Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS) (DOMINUS)
International Multi-center Open-label Randomized Clinical Trial of Efficacy, Safety and Pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) Monotherapy Compared to Docetaxel as Second-line Therapy of Patients With Advanced Inoperable or Metastatic Non-small Cell Lung Cancer
Sponsor: Biocad
This PHASE2/PHASE3 trial investigates Non Small Cell Lung Cancer Stage IIIB and Non-Small Cell Carcinoma of Lung, TNM Stage 4 and is currently ongoing. Biocad leads this study, which shows 11 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Nov 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jun 2019 — Nov 2020 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
May 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2017 — Mar 2018 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Sep 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biocad
For direct contact, visit the study record on ClinicalTrials.gov .